Background: Saline nasal irrigation is labelled as an add-on treatment in patients with allergic rhinitis (AR). The primary aim of this study was to compare the efficacy of 21-day use of buffered hypertonic saline (BHS) versus normal saline solution (NSS) on reducing nasal symptoms in children with seasonal AR (SAR). Comparing their efficacy on nasal cytology counts (NCC), quality of life, and sleep quality was the secondary aim. Methods: In this 21-day, open-label, randomized controlled study, 36 SAR children (aged 6-13 years) with a Total 5 Symptom Score (T5SS) ≥5 received twice-daily BHS or NSS delivered through a nasal douche. Efficacy measures were least square mean changes (LSmc) in T5SS, NCC, Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ), and Pittsburgh Sleep Quality Index (PSQI) scores. Results: BHS improved the T5SS total score to a greater extent than NSS (LSmc -6.45 vs. -5.45, p < 0.001). Concerning NCC, BHS significantly reduced the scores of neutrophils (LSmc -0.76, p = 0.004) and eosinophils (LSmc -0.46, p = 0.018), while NSS did not. Similarly, only BHS yielded a significant improvement in the PRQLQ score (LSmc -0.57, p = 0.009), whereas the improvement in PSQI score was comparable between the BHS (LSmc -0.77, p = 0.025) and NSS (LSmc -1.39, p < 0.001) groups. Overall, BHS was well tolerated. Conclusions: In children with SAR, BHS is effective in improving nasal symptoms and NCC, with an associated beneficial effect on quality of life.

Keywords:
Buffered hypertonic solution, Children, Nasal cytology, Quality of life, Nasal symptoms, Seasonal allergic rhinitis
1.
Björkstén B, Clayton T, Ellwood P, Stewart A, Strachan D; ISAAC Phase III Study Group: Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol 2008;19:110-124.
2.
Cibella F, Cuttitta G, La Grutta S, Melis MR, Lospalluti ML, Uasuf CG, Bucchieri S, Viegi G: Proportional Venn diagram and determinants of allergic respiratory diseases in Italian adolescents. Pediatr Allergy Immunol 2011;22:60-68.
3.
Galassi C, De Sario M, Biggeri A, Bisanti L, Chellini E, Ciccone G, Petronio MG, Piffer S, Sestini P, Rusconi F, Viegi G, Forastiere F: Changes in prevalence of asthma and allergies among children and adolescents in Italy: 1994-2002. Pediatrics 2006;117:34-42.
4.
Cibella F, Ferrante G, Cuttitta G, Bucchieri S, Melis MR, La Grutta S, Viegi G: The burden of rhinitis and rhinoconjunctivitis in adolescents. Allergy Asthma Immunol Res 2015;7:44-50.
5.
Röder E, Berger MY, Hop WC, de Groot H, Gerth van Wijk R: The relevance of patient-reported outcomes in a grass pollen immunotherapy trial in children and adolescents with rhinoconjunctivitis. Pediatr Allergy Immunol 2013;24:39-48.
6.
Roberts G, Xatzipsalti M, Borrego L, Custovic A, Halken S, Hellings P, Papadopoulos N, Rotiroti G, Scadding G, Timmermans F, Valovirta E: Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy 2013;68:1102-1116.
7.
Hermelingmeier KE, Weber RK, Hellmich M, Heubach CP, Mösges R: Nasal irrigation as an adjunctive treatment in allergic rhinitis: a systematic review and meta-analysis. Am J Rhinol Allergy 2012;26:e119-e125.
8.
Jeffe JS, Bhushan B, Schroeder JW: Nasal saline irrigation in children: a study of compliance and tolerance. Int J Pediatr Otorhinolaryngol 2012;76:409-413.
9.
Satdhabudha A, Poachanukoon O: Efficacy of buffered hypertonic saline nasal irrigation in children with symptomatic allergic rhinitis: a randomized double-blind study. Int J Pediatr Otorhinolaryngol 2012;76:583-588.
10.
Hauptman G, Ryan MW: The effect of saline solutions on nasal patency and mucociliary clearance in rhinosinusitis patients. Otolaryngol Neck Surg 2007;137:815-821.
11.
Juniper EF, Stahl E, Doty RL, Simons FER, Allen DB, Howarth PH: Clinical outcomes and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol 2005;115:S390-S413.
12.
Howarth PH, Persson CG, Meltzer EO, Jacobson MR, Durham SR, Silkoff PE: Objective monitoring of nasal airway inflammation in rhinitis. J Allergy Clin Immunol 2005;115:S414-S441.
13.
Baiardini I, Villa E, Rogkakou A, Pellegrini S, Bacic M, Compalati E, Braido F, Le Grazie C, Canonica G, Passalacqua G: Effects of mometasone furoate on the quality of life: a randomized placebo-controlled trial in persistent allergic rhinitis and intermittent asthma using the Rhinasthma questionnaire. Clin Exp Allergy 2011;41:417-423.
14.
Juniper EF, Howland WC, Robertsa NB, Thompson AK, King DR: Measuring quality of life in children with rhinoconjunctivitis. J Allergy Clin Immunol 1998;101:163-170.
15.
Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
16.
Gelardi M, Iannuzzi L, Quaranta N, Landi M, Passalacqua G: NASAL cytology: practical aspects and clinical relevance. Clin Exp Allergy 2016;46:785-792.
17.
Bernstein IL, Li JT, Bernstein DI, Hamilton R, Spector SL, Tan R, Sicherer S, Golden DBK, Khan DA, Nicklas RA, Portnoy JM, Blessing-Moore J, Cox L, Lang DM, Oppenheimer J, Randolph CC, Schuller DE, Tilles SA, Wallace DV, Levetin E, Weber R: Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol 2008;100:S1-S148.
18.
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens W, Togias A, Zuberbier T, Baena-Cagnani C, Canonica G, van Weel C, et al: Allergic rhinitis and its impact on asthma (ARIA) 2008 update. Allergy 2008;63:8-160.
19.
Marchisio P, Varricchio A, Baggi E, Bianchini S, Capasso M, Torretta S, Capaccio P, Gasparini C, Patria F, Esposito S, others: Hypertonic saline is more effective than normal saline in seasonal allergic rhinitis in children. Int J Immunopathol Pharmacol 2012;25:721-730.
20.
Garavello W, Di Berardino F, Romagnoli M, Sambataro G, Gaini RM: Nasal rinsing with hypertonic solution: an adjunctive treatment for pediatric seasonal allergic rhinoconjunctivitis. Int Arch Allergy Immunol 2005;137:310-314.
21.
Garavello W, Romagnoli M, Sordo L, Gaini RM, Berardino CD, Angrisano A: Hypersaline nasal irrigation in children with symptomatic seasonal allergic rhinitis: a randomized study. Pediatr Allergy Immunol 2003;14:140-143.
22.
Greiff L, Andersson M, Wollmer P, Persson C: Hypertonic saline increases secretory and exudative responsiveness of human nasal airway in vivo. Eur Respir J 2003;21:308-312.
23.
Baraniuk JN, Ali M, Yuta A, Fang S, Naranch K: Hypertonic saline nasal provocation stimulates nociceptive nerves, substance P release, and glandular mucous exocytosis in normal humans. Am J Respir Crit Care Med 1999;160:655-662.
24.
Luk CK, Dulfano MJ: Effect of pH, viscosity and ionic-strength changes on ciliary beating frequency of human bronchial explants. Clin Sci 1983;64:449-451.
25.
Homer J, England R, Wilde A, Harwood G, Stafford N: The effect of pH of douching solutions on mucociliary clearance. Clin Otolaryngol Allied Sci 1999;24:312-315.
26.
Talbot AR, Herr TM, Parsons DS: Mucociliary clearance and buffered hypertonic saline solution. Laryngoscope 1997;107:500-503.
27.
Pujara CP, Shao Z, Duncan MR, Mitra AK: Effects of formulation variables on nasal epithelial cell integrity: biochemical evaluations. Int J Pharm 1995;114:197-203.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.